同步原发癌发生在1.7%的乳腺癌病例中,而化生性乳腺癌(MBC)发生在不到1%的乳腺癌病例中。我们介绍了一名先前健康的66岁女性,该女性在手术切除假定的囊肿后被诊断为MBC。第二个原发性癌症,多灶性肺腺癌,是在她的MBC分期过程中发现的.值得注意的是,她在诊断时没有出现肺部或全身症状。她接受了紫杉醇和卡铂的化疗,其次是nivolumab免疫疗法。在她最初诊断后24个月的随访中,她没有乳腺癌,肺结节稳定.该病例强调,而不是假设多灶性病变代表转移,应考虑活检,因为在存在同步癌症的情况下,临床管理可能会显著改变.此外,基于铂的化疗药物有可能被考虑用于治疗MBC。
Synchronous primary cancers occur in 1.7% of breast cancer cases and metaplastic breast cancer (MBC) occurs in less than 1% of breast cancer cases. We present a previously healthy 66-year-old woman diagnosed with MBC after surgical resection of a presumed cyst. A second primary cancer, multifocal lung adenocarcinoma, was discovered during the staging process for her MBC. Remarkably she had not experienced pulmonary or constitutional symptoms at the time of diagnosis. She received chemotherapy with paclitaxel and carboplatin, followed by immunotherapy with nivolumab. At 24 months of follow-up after her initial diagnosis, she was breast cancer-free with stable pulmonary nodules. This case highlights that rather than assuming multifocal lesions represent metastasis, biopsies should be considered as clinical management could be significantly altered in the presence of a synchronous cancer. Furthermore, platinum-based chemotherapy agents have potential to be considered in the treatment of MBC.